Stable versus partial response in advanced prostate cancer
Nelson H. Slack
National Prostatic Cancer Project, Roswell Park Memorial Institute, Buffalo, New York
Search for more papers by this authorMark F. Brady
National Prostatic Cancer Project, Roswell Park Memorial Institute, Buffalo, New York
Search for more papers by this authorCorresponding Author
Gerald P. Murphy MD
National Prostatic Cancer Project, Roswell Park Memorial Institute, Buffalo, New York
Roswell Park Memorial Institute, 666 Elm Street, Buffalo, NY 14263Search for more papers by this authorNelson H. Slack
National Prostatic Cancer Project, Roswell Park Memorial Institute, Buffalo, New York
Search for more papers by this authorMark F. Brady
National Prostatic Cancer Project, Roswell Park Memorial Institute, Buffalo, New York
Search for more papers by this authorCorresponding Author
Gerald P. Murphy MD
National Prostatic Cancer Project, Roswell Park Memorial Institute, Buffalo, New York
Roswell Park Memorial Institute, 666 Elm Street, Buffalo, NY 14263Search for more papers by this authorAbstract
Stable response to therapy in patients with advanced prostate cancer, as experienced in clinical trials of the National Prostatic Cancer Project (NPCP), has been reexamined. Data from ten complete trials totaling over 1,300 patients have been examined for survival patterns within categories of response to therapy. Survival patterns, both for all patients and for those alive at 12 weeks, were significantly poorer for patients categorized as progressors after 12 weeks on treatment than for those categorized as stable or as partial regressions. Furthermore, comparisons of survival patterns for those patients categorized as stable or partial regression revealed no statistically significant differences between them. The similarity of survival for the stable and partial regression categories indicates that the stable category represents more than a segment of the population with slowly progressing disease and can be taken as an indicator of response to therapy.
References
- 1 Scott WW, Gibbons RP, Johnson DE, Prout GR Jr, Schmidt JD, Chu TM, Gaeta JF, Joiner J, Saroff J, Murphy GP: Comparison of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in patients with advanced carcinoma of the prostate. Cancer Chemother Rep 59: 195–201, 1975.
- 2 Moore GE, Bross IDJ, Ausman R, Nadler S, Jones R Jr, Slack NH, Rimm AA: Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer. Eastern Clinical Drug Evaluation Program. Cancer Chemother Rep 52: 641–653, 1968.
- 3 Schmidt JD, Johnson DE, Scott WW, Gibbons RP, Prout GR Jr, Murphy GP: The National Prostatic Cancer Project. Chemotherapy of advanced prostatic cancer, evaluation of response parameters. Urology 7: 602–610, 1976.
- 4
Bailar JC III,
Byar DP,
Veterans Administration Cooperative Urological Research Group:
Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo.
Cancer
26:
257–261,
1970.
10.1002/1097-0142(197008)26:2<257::AID-CNCR2820260203>3.0.CO;2-9 PubMed Web of Science® Google Scholar
- 5 Flocks RH: Clinical cancer of the prostate. JAMA 193: 559–562, 1965.
- 6 Nesbit RM, Baum WC: Endocrine control of prostatic carcinoma. Clinical and statistical survey of 1,818 cases. JAMA 143: 1317–1320, 1950.
- 7 Coune A: Carcinoma of the prostate. In MJ Stagnet (ed): “ Randomized Trials in Cancer: A Critical Review by Sites.” New York: Raven Press, 1978, pp 389–409,
- 8
Franks LM:
Etiology, epidemiology, and pathology of prostatic cancer.
Cancer
32:
1092–1095,
1973.
10.1002/1097-0142(197311)32:5<1092::AID-CNCR2820320513>3.0.CO;2-Z CAS PubMed Web of Science® Google Scholar
- 9
Whitmore WF:
The natural history of prostatic cancer.
Cancer
32:
1104–1112,
1973.
10.1002/1097-0142(197311)32:5<1104::AID-CNCR2820320515>3.0.CO;2-T PubMed Web of Science® Google Scholar
- 10
Slack NH,
Mittelman A,
Brady MF,
Murphy GP, and
Investigators in the National Prostatic Cancer Project:
The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostatic cancer.
Cancer
46:
2393–2402,
1980.
10.1002/1097-0142(19801201)46:11<2393::AID-CNCR2820461115>3.0.CO;2-6 CAS PubMed Web of Science® Google Scholar
- 11 Schmidt JD, Scott WW, Gibbons R, Johnson DE, Prout GR Jr, Loening S, Soloway M, deKernion J, Pontes JE, Slack NH, Murphy GP: Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer 45: 1937–1946, 1980.
- 12 Slack NH, Karr JP, Chu TM, Murphy GP, Investigators in the National Prostatic Cancer Project. Overview of chemotherapy programs of the NPCP. The Prostate 1: 367–373, 1980.
- 13 Soloway MS, deKernion JB, Gibbons RP, Johnson DE, Loening SA, Pontes JE, Prout GR Jr, Schmidt JD, Scott WW, Chu TM, Gaeta JF, Slack NH, Murphy GP: Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced hormone refractory, previously irradiated carcinoma of the prostate. J Urol 125: 664–667, 1981.
- 14 Loening SA, Scott WW, deKernion J, Gibbons RP, Johnson DE, Pontes JE, Prout GR Jr, Schmidt JD, Soloway MS, Chu TM, Gaeta JF, Slack NH, Murphy GP: A comparison of hydroxyurea, methylchloroethyl-cyclohexy-nitrosourea, and cyclophosphamide in patients with advanced carcinoma of the prostate. J. Urol 125: 812–816, 1981.
- 15
Murphy GP,
Beckley S,
Chu TM,
deKernion JB,
Gaeta JF,
Gibbons RP,
Loening SA,
McKiel CF,
McLeod DG,
Pierce JM,
Pontes JE,
Prout GR Jr,
Scardino PT,
Schlegel JU,
Schmidt JD,
Scott WW,
Slack NH,
Soloway MS:
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone.
Cancer
51:
1264–1272,
1983
10.1002/1097-0142(19830401)51:7<1264::AID-CNCR2820510716>3.0.CO;2-U CAS PubMed Web of Science® Google Scholar
- 16 Gibbons RP, Beckley S, Brady MF, Chu TM, deKernion JB, Dhabuwala C, Gaeta JF, Loening SA, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway MS, Murphy GP: The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate. J Surg Oncol 23: 133–142, 1983.
- 17 Loening SA, Beckley S, Chu TM, deKernion JB, Gaeta JF, Gibbons RP, McKiel CF, McLeod DG, Pierce JM, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway MS, Murphy GP: Comparison of estramustine phosphate (Emcyt), methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol 129: 1001–1006, 1983.
- 18 Soloway MS, Beckley S, Chu TM, deKernion JB, Gaeta JF, Gibbons RP, Loening SA, McKiel CF, McLeod DG, Pierce JM, Pontes JE, Prout GR Jr, Scardino PT, Schlegel JR, Schmidt JD, Scott WW, Slack NH, Murphy GP: A Comparison of Emcyt versus cis-platninum alone versus Emcyt plus cis-platinum in patients with advanced hormone refractory prostate cancer who have had extensive irradiation to the pelvis or lumbosacral Area. J. Urol 129: 56–61, 1983.
- 19 Chu TM, Wang MC, Lee CL, Killian CS, Valenzuela LA, Wajsman Z, Slack NH, Murphy GP: Enzyme markers for prostate cancer. Cancer Detect Prev 2: 693–706, 1979.
- 20 Lee CL, Chu TM, Wajsman LZ, Slack NH, Murphy GP: Value of new fluorescent immunoassay for human prostatic acid phosphatase in prostatic cancer. Urology 15: 338–341, 1980.
- 21 Killian CS, Vargas FP, Lee CL, Wang MC, Murphy GP, Chu TM: Quantitative counter immuno-electrophoresis assay for prostate acid phosphatase. Invest Urol 18: 219–244, 1980.
- 22 Killian CS, Vargas FP, Pontes EJ, Beckley S, Slack NH, Murphy GP, Chu TM: The use of serum isoenzymes of alkaline and acid phosphatase as possible quantitative markers of tumor load in prostate cancer. The Prostate 2: 187–206, 1981.
- 23 Wang MC, Kuriyma M, Papsidero LB, Loor RM, Valenzula LA, Murphy GP, Chu TM: Prostate antigen of human cancer patients. In H Bush, L Yoman (eds): “ Methods in Cancer Research.” Vol 19. New York: Academic Press, 1982, pp 179–197,
- 24 Murphy GP, Slack NH: Response criteria for the prostate of the USA National Prostatic Cancer Project. The Prostate 1: 375–382, 1980.
- 25 Cutler SJ, Ederer F: Maximum utilization of the life table method in analyzing survival. J Chron Dis 8: 699–712, 1958.
- 26 Snedecor GW, Chochran WG: “ Statistical Methods,” 6th Ed. Ames, Iowa: Iowa University Press, 1967.
- 27 Bross IDJ: Is there an increased risk? Fed Proc 13: 815–819, 1954.
- 28 Petro R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observations of each patient. Br J Cancer 35: 1–39, 1977.
- 29 JD Kalbfleisch, RL Prentice (eds): “ The Statistical Analysis of Failure Time Data.” New York: John Wiley, 1980, pp 79–84,
- 30 Slack NH, Brady MF, Murphy GP, Investigators in the National Prostatic Cancer Project: A re-examination of the stable category for evaluating response in patients with advanced prostate cancer. Cancer 1984 (in press).
- 31 Yagoda A, Watson RC, Natale RB, Barzell W, Sogani P, Grabstald H, Whitmore WF: A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer 1553–1562, 1979.
- 32 Citrin DL, Cohen AI, Harberg J, Schlise S, Hougen C, Benson R: Systemic treatment of advanced prostatic cancer: Development of a new system for defining response. J Urol 125: 224–227, 1981.
- 33
Citrin DL,
Hogan TF:
A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer.
Cancer
50:
201–206,
1982.
10.1002/1097-0142(19820715)50:2<201::AID-CNCR2820500205>3.0.CO;2-7 CAS PubMed Web of Science® Google Scholar
- 34 Menon M, Catalona WJ: Interpreting response to treatment in advanced prostatic cancer. Reviews on endocrine-related cancer. 10: 11–17, 1981.
- 35 Eagan RT, Hahn RG, Myers RP: Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC 26271) in the treatment of metastatic prostate cancer. Cancer Treat Rep 60: 115–117, 1976.
- 36 DeWys WD, Bauer M, Colsky J, Cooper RA, Creech R, Carbone PP: Comparative trial of adriamycin and 5-flourouracil in advanced prostatic cancer—progress report. Cancer Treat Rep 61: 325–328, 1977.
- 37 Slack NH, Bross IDJ: The influence of site of metastasis on tumor growth and response to chemotherapy. Br J Cancer 32: 78–86, 1975.
- 38 Pollen JJ, Gerber K, Ashburn WL, Schmidt JD: The value of nuclear bone imaging in advanced prostatic cancer. J Urol 125: 222–223.